Phase II Multicenter Study of Talimogene Laherparepvec in Classic or

Status Recruiting

Clinical Trial Summary

Kaposi Sarcoma (KS) is a lymphangioproliferation associated with human herpes virus 8 (HHV8) promoted by immunosuppression. HIV-related KS and iatrogenic posttransplantation KS are treated by immune restoration, in association with local or systemic therapies as chemotherapies if required. Conversely in classic and endemic KS, the underlying relative immunosuppression cannot be directly targeted. Treatment is poorly codified, mostly based on surgery or radiotherapy for localized KS. Most aggressive forms with visceral involvement are treated with chemotherapies or interferon, which give at best 30-60% of transient responses and may not be well tolerated in elderly patients. Talimogene laherparepvec is the first oncolytic immunotherapy approved by the FDA, in metastatic or unresectable melanoma with injectable nodal or cutaneous lesions. It is designed to induce tumor regression of injected lesions through direct lytic effects, and of uninjected lesions through induction of systemic antitumor immunity. In Merkel cell carcinoma (MCC), another virus-induced tumor, treatment with PD-1/PD-L1 axis inhibitors have proven efficacy, thus providing a proof of principle that immunotherapy could be effective in virus-induced tumors. Two cases of metastatic MCC successfully treated with talimogene laherparepvec were recently reported, suggesting that talimogene laherparepvec may also be an effective therapeutic option. Considering the high immunogenicity of viral epitopes in KS tumors, the role of the immune evasion in the development of KS, and the cutaneous manifestations (>90% of patients) that can be easily injected, classic and endemic KS is a good tumor model to be targeted with talimogene laherparepvec. The main objective is to assess whether talimogene laherparepvec is clinically inactive (partial+complete response probability π0<10%) or truly active (partial+complete response probability π1>40%) in classic and endemic Kaposi sarcoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04065152
Study type	Interventional
Source	Assistance Publique - Hôpitaux de Paris
Contact	Julie Delyon, MD PhD
Phone	142385311
Email	julie.delyon@aphp.fr
Status	Recruiting
Phase	Phase 2
Start date	January 1, 2021
Completion date	February 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04941274` - Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma	Phase 1/Phase 2
Completed	`NCT03160183` - Investigating Chemotherapy Treatments, Response and Subsets of HIV-associated Kaposi Sarcoma in Malawi
Recruiting	`NCT03993106` - A Study of sEphB4-HSA in Kaposi Sarcoma	Phase 2
Recruiting	`NCT05081141` - HHV8 and Solid Organ Transplantation
Completed	`NCT00395278` - Development of Serologic Assays for Human Herpes Virus-8
Recruiting	`NCT02408861` - Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	Phase 1
Completed	`NCT03296553` - Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.	Phase 2
Recruiting	`NCT04305691` - Trial of Ixazomib for Kaposi Sarcoma	Phase 2
Completed	`NCT03316274` - Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma	Early Phase 1
Recruiting	`NCT05859074` - A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer	Phase 1
Terminated	`NCT04893018` - NT-I7 for Kaposi Sarcoma in Patients With or Without HIV	Phase 1
Recruiting	`NCT06375122` - Natural History Study of Kaposi Sarcoma
Recruiting	`NCT05663502` - Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
Recruiting	`NCT05329792` - L19IL2/L19TNF in Skin Cancer Patients	Phase 2
Not yet recruiting	`NCT05411237` - Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma	Phase 3
Completed	`NCT03050788` - Smartphone Confocal Microscopy for Diagnosing Kaposi's Sarcoma	N/A
Completed	`NCT03404297` - Compression Therapy for Leg Ulcers and Kaposi Sarcoma in Western Kenya	N/A
Terminated	`NCT01412515` - A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma	Phase 2
Not yet recruiting	`NCT06004011` - AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW)	N/A
Withdrawn	`NCT02229981` - Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma — KAPVEC

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms